Absolutely a possibility. There are several items of interest that the company has remained silent about over the last two weeks. The start of the Long Hauler trial, NASH, the HIV BLA, and perhaps even the EUA application process for CD12 itself.

I would not be surprised if between now and Monday morning management played 'catch up' with press releases in the hopes of changing the narrative at the open. It would also explain the need for 90 minutes for the Q&A session.